Disodium Ascorbyl Phytostanyl Phosphates (FM-VP4) reduces plasma cholesterol concentration, body weight and abdominal fat gain within a dietary-induced obese mouse model

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 8, Issue 3, 2005, Pages 400-408

  Looije, Norbert A ^a   Risovic, Verica ^a   Stewart, David J ^b   Debeyer, Daniel ^b   Kutney, James ^b   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Forbes Medi Tech Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; DISODIUM ASCORBYL PHYTOSTANYL PHOSPHATE; FM VP4; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIETARY INTAKE; DRUG STRUCTURE; ENZYME ASSAY; FLUID INTAKE; FOOD INTAKE; LIPID DIET; LOW FAT DIET; MALE; MEDICAL RECORD; NONHUMAN; OBESITY; RAT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ABDOMINAL FAT; ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; CHOLESTEROL; DIET, FAT-RESTRICTED; DIETARY FATS; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED C57BL; OBESITY; PHYTOSTEROLS;

EID: 27444439374     PISSN: 14821826     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Marx J. Cellular warriors at the battle of the bulge. Science 299:846-849 (2003).
2. Fernandez-Lopez JA, Remesar X, Foz M, Alemany M. Pharmacological approaches for the treatment of obesity. Drugs 62(6):915-944, (2002).
3. Katzmarzyk PT. The Canadian obesity epidemic, 1985-1998. CMAJ, 166(8); 1039-1040 (2002)
4. Ng AW, Lukic T, Pritchard PH, Wasan KM. Development of novel water-soluble phytostanol analogs: disodiurn ascorbyl phytostanyl phosphates (FM-VP4): preclinical pharmacology, pharmacokinetics and toxicology. Cardiovasc Drug Rev. 21: 151-168 (2003).
5. Lukic T, Wasan KM, Zamfir D, Moghadasian MH, Pritchard PH. Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice. Metabolism 52: 425-431 (2003).
6. Wasan KM, Zamfir C, Pritchard PH, Pederson RA. Influence of phytostanol phosphoryl ascorbate (FM-VP4) on insulin resistance, hyperglycemia, plasma lipid levels and gastrointestinal absorption of exogenous cholesterol in Zucker (fa/fa) fatty and lean rats. J Pharm Sci 92: 281-288 (2003).
7. Wasan KM, Najafi S, Peteherych KD, Pritchard PH: Effects of a novel hydrophilic phytostanol analog on plasma lipid concentrations in gerbils. J Pharm Sci 90:1795-1799, (2001).
8. Wasan KM, Najafi S, Wong J, Kwong M, Pritchard PH: Assessing plasma lipid levels, body weight and hepatic and renal toxicity following chronic oral administration of a water soluble phytostanol compound, FM-VP4, to gerbils. J Pharm Pharmaceut Sci4:228-234,(2001).
9. Wasan KM, Peteherych KD, Najafi S, Zamfir C, Pritchard PH: Assessing the plasma pharmacokinetics, tissue distribution, excretion and effects on cholesterol pharmacokinetics of a novel hydrophilic compound, FM-VP4, following administration to rats. J Pharm Pharmaceut Sci 4:207-216,(2001).
10. Cullen P, G. Assmann. High-risk strategies for atherosclerosis. Clin. Chim. Acta. 286(1-2):31-45 (1999).
11. Hendriks HFJ, J.A. Weststrate, T. van Vliet, G.W. Meijer. Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolemic and mildly hypercholesterolemic subjects. Eur. J. Clin. Nutr. 53:319-327 (1999).
12. Hallikainsen MA, MI Uusitupa. Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hyper-cholesterolemic subjects. Am. J. Clin. Nutr. 69:403-410 (1999).
13. Gylling, H, T.A. Miettinen. Cholesterol reduction b different plant stanol mixtures and with variable fat intake. Metabolism 48:575-580 (1999).
14. Jones PJH, F.Y. Ntanios, M. Raeini-Sarjaz, C.A. Vanstone. Cholesterol-lowering efficacy of a sitostanol-containing phytosterol mixture with a prudent diet in hyperlipidemic man. Am. J. Clin. Nutr. 69:1144-1150 (1999).
15. Weststrate JA, G. W. Meijer. Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolemic and mildly hypercholesterolemic subjects. Eur. J. Clin. Nutr. 52:334-343 (1998).
16. Jones PJ, T. Howell, D.E. MacDougall, et al. Short-term administration of tall oil phytosterols improves plasma lipid profiles in subjects with different cholesterol levels. Metabolism 47:751-756 (1998).
17. Gylling H, R. Radhakrishnan, T.A. Miettinen. Reduction of serum choleserol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. Circulation 96:4266-4231 (1997).
18. Gylling H, T.A. Miettinen. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterollemic non-insulin dependent diabetic men. J. Lipid Res. 37:1776-1785 (1996).
19. Miettinen TA, P. Puska, H. Gylling, et al. Reduction of serum cholesterol with sitostanol-ester margarine is a mildly hypercholesterolemic population. New England J. Med.333:1308-1312 (1995).
20. Gylling H, M.A. Siimes, T.A. Miettinen. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J. Lipid Res. 3,6:1807-1812 (1995).
21. Vanhanen HT, J. Kajander, H. Lehtovirta, T.A. Miettinen. Serum levels, absorption efficacy, fecal elimination and synthesis of cholesterol during increasing dosing of dietary sitostanol esters in hypercholesterolemic subjects. Clin. Sci. 87:61-67 (1994).
22. Gylling H, T.A. Miettinen. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia. 37:773-780 (1994).
23. Becker M, D. Staab, K. Von Bergmann. Treatment of severe familial hypercholesterolemia in childhood with sitosterol and sitostanol. J. Pediatr. 122:292-296 (1993).
24. 1, receptor antagonist treatment in diet-induced obese mice. European Journal of Pharmacology 462: 125-132 (2003).
25. Henry M, Ghibaudi L, Gao J, Hwa JJ.Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors. Obes Res. 2005 Jan;13(1):36-47.